NC startup raises $17.5M as it explores alternative to the EpiPen


A Triangle pharmaceutical startup has raked in $17.5 million to fund commercialization of a nasal-spray that the company thinks could serve as an alternative to the EpiPen.

Previous Aurora Health Care leads admissions decline trend
Next Craig Hospital CEO: Diversity in health care is 'a grade school to grad school problem'